[
  {
    "id": "fc_lung_cancer_chemo_85f023d4",
    "front": "INH neurotoxicity: mechanism?",
    "back": "Functional pyridoxine (B6) deficiency",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_ac91d63e",
    "front": "High-risk for INH neuropathy?",
    "back": "Diabetes, HIV, renal disease, alcohol abuse, malnutrition, pregnant, elderly",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_14a83801",
    "front": "Routine pyridoxine dose with INH?",
    "back": "25-50 mg with each INH dose",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_80c714d0",
    "front": "INH neuropathy despite pyridoxine?",
    "back": "Increase pyridoxine to 100 mg daily",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_d24d23bb",
    "front": "INH toxicity seizures: acute treatment?",
    "back": "Hospitalize, IV pyridoxine, antiepileptics",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_f8b684f8",
    "front": "INH: high-risk, pyridoxine dose?",
    "back": "25-50 mg with each INH dose",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_1dfe68f3",
    "front": "INH: pyridoxine if which conditions?",
    "back": "Diabetes, HIV, renal disease, alcohol abuse, malnutrition, pregnant, elderly",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_5f86986b",
    "front": "NTM infection HCT: early or late?",
    "back": "Uncommon early, increasingly recognized as late problem.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_8dff3dc4",
    "front": "NTM prevalence in allogeneic HCT?",
    "back": "2.7%, markedly higher than general population.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_b691eb15",
    "front": "NTM HCT: most common presentation?",
    "back": "Lung disease (93%) at median 343 days post-HCT.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_a3379827",
    "front": "NTM in HCT: associated factors?",
    "back": "Severe chronic GVHD, CMV viremia.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_39e43851",
    "front": "Early NTM HCT: non-pulmonary infections?",
    "back": "Central catheter-associated, skin infections.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_b4110628",
    "front": "NTM infection timing post-HCT?",
    "back": "Late infectious problem.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_90255839",
    "front": "NTM prevalence in HCT recipients?",
    "back": "2.7% of allogeneic HCT recipients.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_e5c241f3",
    "front": "Most common NTM presentation post-HCT?",
    "back": "Lung disease (93% of cases).",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_75cc87a9",
    "front": "Median time NTM lung disease post-HCT?",
    "back": "343 days after HCT.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_befbc4b3",
    "front": "NTM infection post-HCT associated factors?",
    "back": "Severe chronic GVHD, CMV viremia.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  },
  {
    "id": "fc_lung_cancer_chemo_11d2ea25",
    "front": "NTM lung disease after HCT?",
    "back": "Median 343 days post-HCT; 93% cases lung disease.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Lung Cancer - Chemotherapy and Targeted Therapy",
    "bookId": "lung_cancer_chemo",
    "sourceSection": "Stage IV NSCLC and Systemic Therapy",
    "sourceLocation": {
      "bookName": "MurrayNadel_Section_4_OCR",
      "chapter": "PART 2 ⚫ Diagnosis and Evaluation of Respiratory Disease",
      "section": "Stage IV NSCLC and Systemic Therapy",
      "pageNumber": 232
    }
  }
]